Isatuximab Plus Carfilzomib, Dexamethasone Extends PFS in Relapsed Multiple Myeloma
Isatuximab (Sarclisa) added to carfilzomib and dexamethasone significantly prolonged progression-free survival in patients with relapsed multiple myeloma, according to results from the Phase 3 IKEMA clinical trial.
The randomized, multi-center, open label trial enrolled 302 patients with relapsed multiple myeloma who had previously been treated with 1-3 anti-myeloma therapies. During the trial, participants were administered isatuximab through an intravenous infusion at a dose of 10mg/kg one time per week for 4 weeks, then every other week for 28-day cycles in combination with carfilzomib twice weekly.
“When Sarclisa was added to standard-of-care treatment carfilzomib and dexamethasone in this phase 3 trial, results clearly demonstrated a significant reduction in risk of disease progression or death,” said John Reed, MD, PhD, Global Head of Research and Development at Sanofi, in a press release. “This is the second positive phase 3 trial for Sarclisa, further supporting the potential our medicine has to improve outcomes for patients struggling with relapsed multiple myeloma.”
Sanofi plans to submit full results to an upcoming medical meeting later this year.
Read the press release here.